Abstract
Background
Transapical aortic valve replacement (TAVR) is increasingly being applied in conventionally inoperable patients with aortic stenosis. The utility of the cardiac marker NT-pro-BNP has yet not been assessed in this setting.
Methods
NT-pro-BNP was assessed preoperatively, postoperatively (day 1, 3, 5 and 8) and 2 months after the intervention in 31 consecutive patients (13 men, 18 women; median age 84) undergoing TAVR and the association with baseline characteristics and outcome was analysed.
Results
Baseline NT-pro-BNP was associated with baseline creatinine, left-ventricular mass index and NYHA class and predicted regression of LV-mass after 2 months. There was no correlation of NT-pro-BNP with measures of the aortic valve function before or after replacement. The increase of NT-pro-BNP 3 days after TAVR was inversely associated with a functional improvement of ≥1 NYHA class at 2 months. Baseline NT-pro-BNP was not associated with 2-month mortality and major adverse events (death/neurological deficit), whereas the postoperative increase of NT-pro-BNP after TAVR showed a slightly significant inverse and the EuroSCORE a significant correlation.
Conclusions
In multimorbid patients undergoing TAVR, NT-pro-BNP independently predicted regression of LV-mass after 2 months and early decrease of NT-pro-BNP postoperatively indicated improvement of functional capacity at 2 months. There was no association of NT-pro-BNP with 2-month mortality.
Similar content being viewed by others
References
Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R, Piazza R, Cappelletti P, Rubin D, Cassin M, Faggiano P, Nicolosi GL (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128:406–412
Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder T, Pacher R, Maurer G, Baumgartner H (2004) Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109:2302–2308
Bergler-Klein J, Mundigler G, Pibarot P, Burwash IG, Dumesnil JG, Blais C, Fuchs C, Mohty D, Beanlands RS, Hachicha Z, Walter-Publig N, Rader F, Baumgartner H (2007) B-type natriuretic peptide in low-flow, low-gradient aortic stenosis: relationship to hemodynamics and clinical outcome: results from the Multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study. Circulation 115:2848–2855
Bleiziffer S, Ruge H, Mazzitelli D, Schreiber C, Hutter A, Laborde JC, Bauernschmitt R, Lange R (2009) Results of percutaneous and transapical transcatheter aortic valve implantation performed by a surgical team. Eur J Cardiothorac Surg 35:615–620
Cemri M, Arslan U, Kocaman SA, Cengel A (2008) Relationship between N-terminal pro-B type natriuretic peptide and extensive echocardiographic parameters in mild to moderate aortic stenosis. J Postgrad Med 54:12–16
Georges A, Forestier F, Valli N, Plogin A, Janvier G, Bordenave L (2004) Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. Eur J Cardiothorac Surg 25:941–945
Gerber IL, Legget ME, West TM, Richards AM, Stewart RA (2005) Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 95:898–901
Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A (2003) A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24:1231–1243
Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M (1989) Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 79:744–755
Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivandic B, Katus H, Giannitsis E (2007) Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152–159
Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, Vanoverschelde JL, Carayon A, Gueret P (2004) Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 25:2048–2053
Nessmith MG, Fukuta H, Brucks S, Little WC (2005) Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 96:1445–1448
Neverdal NO, Knudsen CW, Husebye T, Vengen OA, Pepper J, Lie M, Tonnessen T (2006) The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis—1-year follow-up. Eur J Heart Fail 8:257–262
Orlowska-Baranowska E, Baranowski R, Greszata L, Stepinska J (2008) Brain natriuretic peptide as a marker of left ventricular hypertrophy in patients with aortic stenosis. J Heart Valve Dis 17:598–605
Pedrazzini GB, Masson S, Latini R, Klersy C, Rossi MG, Pasotti E, Faletra FF, Siclari F, Minervini F, Moccetti T, Auricchio A (2008) Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 102:749–754
Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA (2004) Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6:289–293
Pfister R, Tan D, Thekkanal J, Hellmich M, Erdmann E, Schneider CA (2007) NT-pro-BNP measured at discharge predicts outcome in multimorbid diabetic inpatients with a broad spectrum of cardiovascular disease. Acta Diabetol 44:91–97
Pfister R, Tan D, Thekkanal J, Hellmich M, Schneider CA (2007) NT-pro-BNP is associated with long-term outcome in a heterogeneous sample of cardiac inpatients. Eur J Intern Med 18:215–220
Scharhag J, Herrmann M, Weissinger M, Herrmann W, Kindermann W (2007) N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease. Clin Res Cardiol 96:218–226
Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP, Kovac J, Ludgate S, Maisano F, Moat N, Mohr F, Nataf P, Pierard L, Pomar JL, Schofer J, Tornos P, Tuzcu M, van Hout HB, Von Segesser LK, Walther T (2008) Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 29:1463–1470
van Kimmenade RR, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, Crijns HJ, van Dieijen-Visser MP, de Leeuw PW, Pinto YM (2009) Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53:884–890
Vanderheyden M, Goethals M, Verstreken S, DeBruyne B, Muller K, VanSchuerbeeck E, Bartunek J (2004) Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 44:2349–2354
Walther T, Simon P, Dewey T, Wimmer-Greinecker G, Falk V, Kasimir MT, Doss M, Borger MA, Schuler G, Glogar D, Fehske W, Wolner E, Mohr FW, Mack M (2007) Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 116:I240–I245
Weber M, Arnold R, Rau M, Brandt R, Berkovitsch A, Mitrovic V, Hamm C (2004) Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94:740–745
Weber M, Arnold R, Rau M, Elsaesser A, Brandt R, Mitrovic V, Hamm C (2005) Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 26:1023–1030
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pfister, R., Wahlers, T., Baer, F.M. et al. Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement. Clin Res Cardiol 99, 301–307 (2010). https://doi.org/10.1007/s00392-010-0118-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-010-0118-x